{"id":725033,"date":"2023-01-23T11:00:02","date_gmt":"2023-01-23T16:00:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/"},"modified":"2023-01-23T11:00:02","modified_gmt":"2023-01-23T16:00:02","slug":"lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/","title":{"rendered":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WHITE PLAINS, N.Y., Jan.  23, 2023  (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fate Therapeutics Inc. (\u201cFate\u201d or the \u201cCompany\u201d) for violations of the federal securities laws on behalf of investors.<\/p>\n<p>Fate Therapeutics (\u201cFate\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders. On April 2, 2020 Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (\u201cJanssen\u201d), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the \u201cJanssen Collaboration Agreement\u201d). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration.<\/p>\n<p>On January 5, 2023, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement. Specifically, the Company disclosed that it was \u201cnot able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023[.]\u201d As a result of the termination, Fate revealed that all licenses and other rights granted pursuant to the Janssen Collaboration Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers, including FT516 and FT538 NK cell programs in acute myeloid leukemia, FT516 and FT596 NK cell programs in B-cell lymphoma, and FT538 and FT536 NK cell programs in solid tumors.<\/p>\n<p>On January 20, 2023, a complaint was filed against Fate and certain of its top officers, alleging that throughout the Class Period (April 2, 2020 to January 5, 2023), Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The Complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company\u2019s business, operations, and compliance policies. Specifically, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement\u2019s on Fate\u2019s long-term clinical and commercial profitability; and (iv) as a result, the Company&#8217;s public statements were materially false and misleading at all relevant times.<\/p>\n<p>When investors learned the truth, Fate\u2019s common stock declined precipitously, injuring investors.<\/p>\n<p>If you suffered a loss in Fate\u2019s securities, and wish to participate, or learn more, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gzyOzjbGOlgo476siDqvzooJrpEjvF-1nWpdgmKRz77xqnv0tD4roxzr3bffRdsPCZMMzPUAF9uLg7SELrn66_uW3fuUMUTOmcU6RuFO0_k=\" rel=\"nofollow noopener\" target=\"_blank\">click here<\/a>, or please contact our attorneys at (914) 733-7234 or via email at investigations@lowey.com.<\/p>\n<p>Any investor who wishes to serve as Lead Plaintiff must act before March 22, 2023.<\/p>\n<p>\n        <strong>About Lowey Dannenberg<\/strong><br \/>\n        <br \/>Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.<\/p>\n<p>\n        <strong>Contact<\/strong>:<br \/>Lowey Dannenberg P.C.<br \/>44 South Broadway, Suite 1100<br \/>White Plains, NY 10601<br \/>Tel: (914) 733-7234<br \/>Email: investigations@lowey.com<\/p>\n<p>\n        <strong>SOURCE<\/strong>: Lowey Dannenberg P.C.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjdjOGU3ZmItNTcxYS00MjU0LThlN2MtNWJjNzU1NzljYTZiLTEyMDYwODc=\/tiny\/Lowey-Dannenberg-P-C-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fate Therapeutics Inc. (\u201cFate\u201d or the \u201cCompany\u201d) for violations of the federal securities laws on behalf of investors. Fate Therapeutics (\u201cFate\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders. On April 2, 2020 Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (\u201cJanssen\u201d), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the \u201cJanssen Collaboration Agreement\u201d). In &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-725033","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fate Therapeutics Inc. (\u201cFate\u201d or the \u201cCompany\u201d) for violations of the federal securities laws on behalf of investors. Fate Therapeutics (\u201cFate\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders. On April 2, 2020 Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (\u201cJanssen\u201d), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the \u201cJanssen Collaboration Agreement\u201d). In &hellip; Continue reading &quot;Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T16:00:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline\",\"datePublished\":\"2023-01-23T16:00:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/\"},\"wordCount\":581,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/\",\"name\":\"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\",\"datePublished\":\"2023-01-23T16:00:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/","og_locale":"en_US","og_type":"article","og_title":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk","og_description":"WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fate Therapeutics Inc. (\u201cFate\u201d or the \u201cCompany\u201d) for violations of the federal securities laws on behalf of investors. Fate Therapeutics (\u201cFate\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders. On April 2, 2020 Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (\u201cJanssen\u201d), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the \u201cJanssen Collaboration Agreement\u201d). In &hellip; Continue reading \"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T16:00:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline","datePublished":"2023-01-23T16:00:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/"},"wordCount":581,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/","name":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=","datePublished":"2023-01-23T16:00:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDcxNCM1MzY5MzU3IzIxOTQ1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-fate-therapeutics-inc-nasdaq-fate-investors-of-securities-class-action-lawsuit-and-upcoming-lead-plaintiff-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=725033"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725033\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=725033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=725033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=725033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}